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National and international consortia will play a key role in understanding the effects of the coronavirus dis-
ease 2019 (COVID-19) pandemic on cancer patients. The COVID-19 and Cancer Consortium (CCC19) aims
to collect and analyze observational data at scale to inform clinical practice in real-time.Background
The rapid spread of the coronavirus dis-
ease 2019 (COVID-19) pandemic has
dramatically impacted oncologic care.
Current evidence suggests that the effect
of the pandemic on cancer patients has
been profound. Two observational
studies suggest that infection rates of
COVID-19 may be significantly higher in
cancer patients than in the general popu-
lation (Liang et al., 2020; Yu et al., 2020).
Further analyses suggest that cancer pa-
tients may also be at increased risk of se-
vere complications from COVID-19,
including hospitalization, respiratory fail-
ure, and death (Dai et al., 2020; Liang
et al., 2020).
Multiple factors are likely contributing
to the increased prevalence and severity
of COVID-19 infection seen in cancer pa-
tients. Compared to the general popula-
tion, cancer patients tend to be older,
are more often smokers, and have more
comorbid medical conditions, all of which
are reported risk factors for severe
COVID-19 infection (Jordan et al., 2020).
Cancer treatment also typically involves
frequent and lengthy visits to healthcare
facilities, which carry risks of viral trans-
mission independent of the treatment
given (Wang et al., 2020). Of major
concern to medical oncologists in partic-
ular are antineoplastic therapies, which
have a variety of effects that can theoret-
ically be deleterious in the context of
COVID-19. Lymphosuppression and
myelosuppression directly caused by
cancer itself as well as cytotoxic treat-738 Cancer Cell 37, June 8, 2020 ª 2020 Elsments pose an increased risk of respira-
tory viral infections (Vento et al., 2008);
some cytotoxic agents also cause pulmo-
nary toxicity that may prove harmful in the
context of severe COVID-19. Some
monoclonal antibodies (for example,
anti-CD38 antibodies such as daratumu-
mab and isatuximab) result specifically
in NK-cell depletion and increase risk of
lower respiratory viral infection, although
it is unclear whether this applies to
COVID-19 (Nahi et al., 2019). Early reports
have demonstrated a hyperactive, proin-
flammatory T cell phenotype in severe
cases of COVID-19 (Xu et al., 2020).
Some clinicians have accordingly hypoth-
esized that immune checkpoint inhibitors
may promote a more severe COVID-19
phenotype and are using these drugs
with some hesitation, although the sub-
ject is controversial (Bersanelli 2020).
Finally, a significant proportion of cancer
patients take corticosteroids for prophy-
laxis, treatment, and symptom control
related to cancer, which might be detri-
mental in the management of acute respi-
ratory distress syndrome due to COVID-
19 (Russell et al., 2020).
Although many oncologists are uncer-
tain about whether they can safely treat
their patients in the face of the concerns
noted above, deferring therapy poses its
own risks. Delays in cancer therapy have
been associated with worse outcomes in
multiple settings, particularly if the intent
of treatment is curative or associated
with a meaningful overall survival benefit
(Biagi et al., 2011; Bleicher et al., 2016;evier Inc.Samson et al., 2015). Prospective clinical
trials of investigational antineoplastic
therapy, which drive many advancements
in medical oncology, are now faced with
additional logistical and practical barriers
in the COVID-19 era. Due to this, many
cancer clinical trials are either on hold or
accruing slowly. In addition, despite
COVID-19-related trials accruing at re-
cord pace, no randomized data are yet
available to guide practice. Notably,
some antineoplastic treatments may be
helpful in mitigating the harmful immune
response associated with severe
COVID-19 and are under active investiga-
tion as repurposed therapies for COVID-
19 (Table 1). Given the above, it is imper-
ative that real-world evidence about the
effects of COVID-19 on cancer patients
is collected and disseminated rapidly to
inform clinical decisions.
The COVID-19 and Cancer
Consortium (CCC19)
The CCC19 is a multicenter registry that
was created to help bridge the knowledge
gap in cancer care caused by the COVID-
19 pandemic. A guiding principle of the
CCC19 is that through crowdsourcing,
the consortium can both reduce barriers
to entry of data and leverage expertise
that is broadly distributed, both in terms
of geography and subject matter, as is
discussed elsewhere in more detail (Desai
et al., 2020). Launched in beta testing on
March 16, 2020, and live on March 17,
2020, the CCC19 now includes more
than 90 institutions at the time of this
Table 1. Selected FDA-Approved Antineoplastic Therapies under Study as Repurposed COVID-19 Treatments as of April 24, 2020
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llwriting, in multiple practice settings
across 28 states, as well as Canada and
Spain (Figure 1A). Participation in the
CCC19 is open and voluntary in nature.
Participating sites are asked to obtain
necessary institutional IRB approval and
data transfer and to make the best
possible effort to report data on cases of
COVID-19 in cancer patients that are
treated in both the inpatient and outpa-
tient settings, to ensure data are collected
on patients with both mild and severe dis-
ease. To avoid duplicate entry of patients,
the CCC19 recommends that data entry
be centralized either through an institu-
tional point person with oncology domain
knowledge or to professional data entry
personnel.
Data are entered through a RedCAP
survey (Harris et al., 2019). Survey build-
out and maintenance, as well as data
maintenance, analysis, and dissemina-tion, are coordinated at Vanderbilt Univer-
sity Medical Center in Nashville, TN. The
founding member institutions of the
CCC19 are Aurora Health Care (Wiscon-
sin), Dana-Farber Cancer Institute (Bos-
ton, MA), Fred Hutchinson Cancer
Research Center (Seattle, WA), Sylvester
Comprehensive Cancer Center (Miami,
FL), and Vanderbilt-IngramCancer Center
(Nashville, TN). The CCC19 is overseen by
a Steering Committee (SC) comprised of
established experts in the fields of clinical
hematology/oncology, virology, epidemi-
ology, biostatistics, patient advocacy,
and informatics, with all SC members
having equal standing.
This nature of data collection, and the
absence of protected health information
being collected, facilitates rapid IRB
approval, often with exemptions, at
participating sites, which in turn enables
the CCC19 to collect large amounts ofdata in a short period of time. To illustrate
this point, fewer than 30 days elapsed be-
tween completion of the first and the
1,000th surveys (Figure 1B). Ultimately,
electronic health record integration is
planned, which will augment the manually
abstracted data and further accelerate
data collection. Of note, a large global
analysis is planned, subsequently fusing
RedCAP databases with the European
Society for Medical Oncology COVID-19
and Cancer Registry (ESMO-CoCARE)
project. As 25% of ESMO members are
located in Asia, this effort is expected to
involve participating sites across three
continents.
TheCCC19 collects data in four primary
domains: (1) deidentified demographic
data and other baseline patient-level
data, including medical comorbidities
that are not related to cancer or to
COVID-19; (2) clinical data pertaining toCancer Cell 37, June 8, 2020 739
Figure 1. Geographic Participation and Patient Accrual in the CCC19
(A) Schematic indicating institutions that are participating in the CCC19 as of April 16, 2020. The sites are a
combination of National Cancer Institute-designated comprehensive cancer centers, academic in-
stitutions, and community-based institutions.
(B) Chart demonstrating exponential growth in reported cases over time (n = 1,040 as of a data lock on
April 16, 2020) for analysis in the first CCC19 publication.
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llCOVID-19, including laboratory values,
severity of COVID-19 presentation, and
treatments received for COVID-19; (3)
data pertaining to cancer diagnosis,
stage, and current and prior treatment;
and (4) follow-up data including outcomes
related to COVID-19 . Data collection on
30-day and 90-day outcomes is also
planned.
As examples, demographic data can be
used to validate published data on
adverse factors for COVID-19, such as740 Cancer Cell 37, June 8, 2020age or pre-existing pulmonary or cardio-
vascular disease. The correlation of out-
comes with the type and timing of anti-
neoplastic therapy received can inform
decisions on the risks and benefits of
starting or continuing specific therapies
in specific tumor types and clinical sce-
narios, or whether certain antineoplastic
therapies may be associated with more
severe COVID-19. The outcomes for pa-
tients receiving various potential anti-
COVID-19 therapies are useful in deter-mining which agents are most rational to
investigate in future prospective clinical
trials.
Collective Wisdom in the Era of
COVID-19
The care of patients with COVID-19 and
cancer is rapidly evolving and expanding
around current geographic, operational,
and bioinformatic boundaries. Driven by
the need to harmonize data, CCC19
has the potential to collect large-scale,
timely real-world data on cancer patients
with COVID-19. Nevertheless, these data
are observational in nature, which intro-
duces the potential for unmeasured con-
founding in any analyses. Data collection
is entirely cross-sectional or retrospec-
tive, although as 30-day and 90-day
outcome surveys are completed, the
data will develop a prospective compo-
nent. Although institutions in a variety of
practice patterns are participating, sites
to date include a large number of tertiary
care centers, which care for a population
of cancer patients that are being treated
with later-line therapy and suffer from
higher numbers of complex medical
problems than cancer patients treated
in the community. This somewhat limits
the external generalizability of studies
conducted using CCC19 data; however,
the same bias holds for most clinical tri-
als that form the evidence base of
oncology. At this time, the geographic
distribution of centers and patients
skews toward the Northeastern United
States, which contains several cities
that have particularly high caseloads.
The reality of the COVID-19 era is that
many of the most urgent questions for
the field involve determining when it is
safe or advisable to deploy the pre-
COVID-19 standard of care. Observa-
tional data, such as that collected
through the CCC19, can be very informa-
tive in answering these types of
questions.
Through a landmark voluntary effort to
crowdsource data collection as well as
innovative collaboration between dedi-
cated oncology professionals, CCC19
will shed light on the answers to some
crucial questions with real-world evi-
dence. We anticipate that the aggregate
data collected through CCC19 will be har-
nessed to increase innovative and agile
ways to answer more specific questions.
In these unprecedented times, such an
Commentary
llinitiative has the potential to improve out-
comes for cancer patients in the United
States and beyond.
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